Long-term and low-dose rituximab treatment for chronic inflammatory demyelinating polyneuropathy.

Yongsheng ZhengChong SunYanyin ZhaoQuanhua MengJianian HuKai QiaoJian SunJianying XiSushan LuoJiahong LuChongbo ZhaoJie Lin

Published in: Journal of the peripheral nervous system : JPNS (2024)

Rituximab presents a promising therapeutic option for idiopathic CIDP, offering both efficacy and safety with a low-dose, long-term regimen.

Keyphrases